Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy for trans individuals is effective and generally safe in the short term.

Women with severe acne, hirsutism, and androgenic alopecia often have higher levels of certain androgens, but the specific pattern can't be predicted just by looking at symptoms.

The MPV/PC ratio can help assess disease activity in alopecia areata.

Minoxidil helps increase hair growth and density in people with hair loss, with higher concentrations giving better results.

We need better research to improve alopecia treatment and patient care.

Genes controlling hair growth and immune response are disrupted in male pattern baldness.

Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.

Captopril may cause hair loss, as shown by a woman's hair regrowing after stopping the medication.

Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.

Scalp cooling prevented hair loss in half of the patients, despite significant side effects.

Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.

The research found that certain characteristics like age, sex, race, marital status, and education level can influence whether alopecia patients stick to their hair loss treatment with topical minoxidil.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.

Personality traits and anxiety affect hair loss patients' quality of life.

Patients with Alopecia Areata are willing to trade life duration for better quality of life.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

Depression severity is not linked to PCOS markers like BMI, insulin resistance, or testosterone levels.

People with Alopecia Areata have a higher risk of heart-related health issues.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

New alopecia treatments aim for better results and fewer side effects.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.